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The peroxisome proliferation-activated receptor
gamma (PPAR) is expressed in many cell types includ-
ing mammary epithelium, ovary, macrophages, and B-
and T-cells. PPAR has an anti-proliferative effect in
pre-adipocytes and mammary epithelial cells, and treat-
ment with its ligands reduced the progression of carcin-
ogen-induced mammary tumors in mice. Because
PPAR-null mice die in utero it has not been possible to
study its role in development and tumorigenesis in vivo.
To investigate whether PPAR is required for the estab-
lishment and physiology of different cell types, a cell-
specific deletion of the gene was carried out in mice
using the Cre-loxP recombination system. We deleted
the PPAR gene in mammary epithelium using WAP-Cre
transgenic mice and in epithelial cells, B- and T-cells,
and ovary cells using MMTV-Cre mice. The presence of
PPAR was not required for functional development of
the mammary gland during pregnancy and for the es-
tablishment of B- and T-cells. In addition, no increase in
mammary tumors was observed. However, loss of the
PPAR gene in oocytes and granulosa cells resulted in
impaired fertility. These mice have normal populations
of follicles, they ovulate and develop corpora lutea. Al-
though progesterone levels are decreased and implan-
tation rates are reduced, the exact cause of the impaired
fertility remains to be determined.
The peroxisome proliferation-activated receptor gamma
(PPAR)1 is a member of the nuclear receptor superfamily. It is
expressed in many cell types, including adipocytes, epithelial
cells, B- and T-cells, macrophages, endothelial cells, neutro-
phils, and smooth muscle cells (1–3). PPAR regulates gene
expression by binding as a heterodimer with retinoid X recep-
tors (RXRs) to specific response elements (PPREs) in the pro-
moter regions of target genes (4, 5). PPAR ligands mediate a
diversity of cellular effects, such as the regulation of adipocytes
differentiation, lipid metabolism, and glucose homeostasis (6–
8). A versatile array of ligands for PPAR includes naturally
occurring compounds such as fatty acids and the prostaglandin
D2 metabolite 15-deoxy-12,14-prostaglandin J2 (15d-PGJ2)
(9). They also include synthetic compounds such as the thiazo-
lidinedione (TZD) class of insulin-sensitizing agents that are
used to treat type II diabetes (10). The extensive use of agonists
in vitro has resulted in some understanding of PPAR function
in adipogenesis. However, the function of PPAR is not re-
stricted to adipogenesis and insulin sensitization (11, 12). In
peripheral monocytes and macrophages, PPAR agonists are
reported to inhibit the production of inflammatory cytokines
(13) and to stimulate lipid metabolism and transport (11).
Furthermore PPAR ligands can induce differentiation and
apoptosis in breast (14–17), prostate cancer cells (18), and
choriocarcinoma cells (19).
Using a traditional gene-targeting approach, PPAR-defi-
cient null embryos have been generated, which die at around
embryonic day 10 because of defects in placental vasculariza-
tion that lead to extensive myocardial thinning (20). A single
PPAR-null embryo that was rescued at term exhibited a lethal
combination of pathologies, including lipodystrophy and mul-
tiple hemorrhages. Because PPAR is found in a broad spec-
trum of cell types, tissue-specific gene targeting of the PPAR
gene is necessary to expand our knowledge of its physiological
role. Conditional disruption of the PPAR gene in macrophages
resulted in lowered expression of ABCA1, ABCG1, and apoE
and reduced cholesterol efflux (21).
In this report, the role of PPAR was investigated by deletion
of the gene in mammary epithelium, ovary, and B- and T-cells
using Cre-loxP-mediated recombination. Mice were generated
that carried loxP sites in the first and second intron of the
PPAR gene (21) and Cre transgenes under control of the whey
acidic protein (WAP) gene promoter and the mouse mammary
tumor virus long terminal repeat (MMTV-LTR) (22, 23).
Through the generation of mice that carry two targeted PPAR
alleles and a Cre transgene, we were able to investigate the
roles of PPAR in mammary gland development and tumori-
genesis, in the ovary and the hematopoietic system.
MATERIALS AND METHODS
Transgenic Mice—Conditional PPAR-null mice were previously
generated by floxing exon 2 of the PPAR gene (21). These mice were
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mated with MMTV-Cre and WAP-Cre transgenic mice (22) and with
ROSA26 reporter mice (24). The genotypes of the mice were determined
by PCR analysis. Primers for the PPAR gene were F (5-ctc caa tgt tct
caa act tac-3), R1 (5-gat gag tca tgt aag ttg acc-3), and R2 (5-gta ttc
tat ggc ttc cag tgc-3), which yielded a 225-bp band from the wild type
allele, a 275-bp band from the floxed allele, or a 400-bp band from the
null allele (95 °C, 30 s; 60 °C, 30 s; 72 °C, 90 s; 35 cycles). Primers for
the Cre transgenes were 5-tag agc tgt gcc agc ctc ttc c-3 (which binds
in the WAP gene promoter), 5-ggt tct gat ctg agc tct gag tg-3 (which
binds in the MMTV-LTR), and 5-cat cac tcg ttg cat cga ccg g-3 (which
binds in the Cre sequence). The WAP-Cre transgene produced a 240-bp
fragment and MMTV-Cre transgene yielded a 280-bp fragment (95 °C,
30 s; 65 °C, 30 s; 72 °C, 1 min; 30 cycles). The ROSA26 transgene
produced a 425-bp product with primers 5-gat ccg cgc tgg cta ccg gc-3
and 5-gga tac tga cga aac gcc tgc c-3 (95 °C, 30 s; 65 °C, 30 s; 72 °C, 1
min; 30 cycles). All products were separated in 2% agarose Tris acetate/
EDTA gels. In the study, all the control mice were PPAR fl/fl
littermates.
Northern Blot—Total RNA from mammary gland samples was iso-
lated at different time points by TRIzol reagent (Invitrogen). Northern
blots were prepared with 20 g of total RNA per lane. The hybridization
probe was an approximate 1-kb BamHI/SpeI fragment from the 3-part
of the PPAR cDNA. The identity of the probe was confirmed by
sequencing.
Histological Evaluation of Mammary Glands and Ovaries—The in-
guinal mammary gland was biopsied at the indicated times of develop-
ment and spread on a glass slide. After fixation for 4 h in Carnoy’s
solution, the glands were hydrated and stained with carminalum and
dehydrated and mounted as described by Kordon et al. (25). The glands
were photographed, paraffin-embedded, and sectioned at 5 m. Sec-
tions were stained with hematoxylin and eosin. For the -galactosidase
assay, the tissues were fixed in 2% paraformaldehyde, 0.25% glutaral-
dehyde, and 0.01% Nonidet P-40 in phosphate-buffered saline for 2 h
and prestained in 2 mM MgCl2, 0.01% (w/v) sodium deoxycholate, and
0.02% (v/v) Nonidet P-40 in phosphate-buffered saline. Following the
prestain, the samples were stained for 24–48 h at 30 °C in 30 mM
K4Fe(CN)6, 30 mM K3Fe(CN)6, 2 mM MgCl2, 0.01% (w/v) sodium deoxy-
cholate, and 0.02% (v/v) Nonidet P-40 in phosphate-buffered saline with
1 mg/ml X-gal (5-bromo-4-chloro-3-indolyl--D-galactopyranoside).
Samples were washed in phosphate-buffered saline and then dehy-
drated, paraffin-embedded, and sectioned. The sections were counter-
stained with nuclear fast red.
Ovaries were fixed in Bouin’s solution overnight and then washed in
70% ethanol. Paraplast (VWR Scientific, Buffalo Grove, IL)-embedded
ovaries were serial-sectioned (8 m) through the entire tissue, mounted
on glass slides, and stained with Weigert’s hematoxylin/picric acid
methylene blue. Every 10th section was analyzed for the number of
primordial, primary, and pre-antral/antral follicle numbers. The num-
ber of follicles in every 10th section was multiplied by 8 in order to give
an estimate of the total follicle numbers. Only the follicles with a visible
nucleus in the oocyte were counted to avoid double counting.
Mammary Epithelium Transplantation—The endogenous epithe-
lium of athymic nude 3-week-old mice was removed as described by
DeOme et al. (26). A piece of mammary tissue from a mature virgin
donor was implanted into the center of the remaining fat pad. Mam-
mary tissues from PPAR fl/fl; MC(F), and fl/fl mice were transplanted
into the right and left sides of the same nude mouse, respectively. To
obtain transplanted tissues at term, the hosts were mated 8 weeks after
they received the transplant, and the mammary glands were harvested
the morning after delivery.
Hormone Level—Progesterone levels were measure by radioimmuno-
assay using Coat-A-Count (Diagnostic Products Corporations, Los An-
geles, CA). Mice were anesthetized, and blood was collected by phlebot-
omy from the retro-orbital plexus. Serum was separated from cells by
centrifugation for 5 min at 5000 rpm. Three 8-week-old PPAR fl/fl;
MC(F) virgin mice and four control mice were checked for estrus cycles,
and blood was collected at the estrus day. Serum from six 8-week-old
fl/fl; MC(F) and six fl/fl pseudopregnant mice (intraperitoneal injection
of 5 IU of pregnant mare serum gonadotropin (PMSG) followed 48 h
later by intraperitoneal injection of 5 IU of human chorionic gonado-
tropin (hCG) every 24 h for a total of 72 h) was analyzed.
Embryo Implantation Sites—Three PPAR fl/fl; MC(F) adult females
and two control females were mated with males of the same strain. The
morning of finding a vaginal plug was designated day 0.5 of pregnancy.
On day 6.5 of pregnancy, implantation sites were visualized by staining
the uterus with 1% ammonium sulfide (Sigma) for 20 min. The implan-
tation sites were identified by the unstained bands along the uterus (the
uterus was stained blue).
Flow Cytometry—Single cell suspensions from spleen were depleted
of erythrocytes and 106 cells were incubated with different combina-
tions of antibodies for two-color fluorescence surface staining. Data
were collected in a FACS calibur flow cytometer (BD PharMingen) and
analyzed using CELLQuest software (BD PharMingen). The following
monoclonal antibodies were used: anti-B220 (clone RA3-6B2), anti-
CD11b (clone MacI), anti-CD4 (clone GK1.5), anti-CD8 (clone 53-6.7)
All the antibodies were purchase from BD PharMingen.
RESULTS
Conditional Deletion of the PPAR Gene in Mouse Tissues—
Because PPAR-null mice die by day E10 (20), it has not been
possible to investigate the function of PPAR in tissue devel-
opment and physiology. To overcome this obstacle, we gener-
ated mice in which the PPAR gene can be deleted in specific
cell types using the Cre-loxP recombination system. Exon 2 of
the PPAR gene was flanked by loxP sites to generate PPAR-
floxed mice (21), which were bred with transgenic mice that
carry the Cre gene under control of either the MMTV-LTR or
the WAP gene promoter (22, 23). Loss of exon 2 leads to a
premature termination of translation (21). Mice that carry
floxed PPAR alleles and the MMTV-Cre transgene are re-
ferred to as fl/fl; MC mice and those carrying the WAP-Cre
transgene as fl/fl; WC mice. The WAP-Cre transgene is ex-
pressed almost exclusively in mammary epithelial cells during
pregnancy and lactation, whereas the MMTV-Cre transgene is
active in many tissues (23). We used two lines of transgenic
mice expressing the MMTV-Cre transgene. While in the D line
(MC(D)) the transgene is expressed in several secretory organs
and the hematopoietic system (23), it is also expressed in ovar-
ian tissue in the F line (MC(F)). The cell-specificity of Cre
expression in the MC(F) line was established using the Rosa26
reporter strain (Fig. 1A). Cre activity was found in mammary
ductal and alveolar epithelium, in the salivary gland, oocytes,
granulosa cells, megacaryocytes, and B- and T-cells, but not in
the uterus. We further evaluated the extent of MC(F)-mediated
excision of exon 2 of the PPAR gene and its tissue distribution
FIG. 1. Conditional deletion of the PPAR gene in mouse tis-
sue. A, LacZ staining of different tissues in MC(F); Rosa26 mouse:
virgin mammary gland (panel I); lactation mammary gland (panel II),
arrows point to mammary epithelial cells in panels I and II, lu, lumen;
uterus (panel III); oocyte (panel IV); granulosa cells in ovary, stained
blue (arrow, panel V); spleen arrow points to the megacaryocyte panel
VI. B, MMTV-Cre(F)-mediated recombination of the PPAR gene in
various cell types by PCR analysis. All the samples were from PPAR
fl/fl mice. , MC(F) positive; , MC(F) negative. Null band (400 bp) is
the recombination product after deletion of exon 2 of the PPAR gene
(primers F/R2). The flox band (275 bp) is from the primers F/R1 with
one loxP insertion.



















by PCR analysis of fl/fl; MC(F) mice. Extensive excision was
observed in mammary tissue, B- and T-cells, and to a lesser
extent in granulosa cells (Fig. 1B). Isolated B- and T-cells from
the spleen of the conditional knockout mice exhibited a high
recombination efficiency of the PPAR gene. There was no
excision of the PPAR gene in the uterus, which demonstrated
the absence of Cre recombinase expression.
PPAR Is Not Required for Functional Mammary Gland
Development—It has been shown that the PPAR gene is ex-
pressed in both normal mammary epithelial cells and stromal
cells (15). We further established the profile of PPAR during
mammary development by using northern blot analyses (Fig.
2A). PPAR mRNA levels were high in virgin tissue and during
pregnancy, decreased during lactation, and were reestablished
at day 4 of involution. Highest levels of PPAR mRNA were
detected in cleared fat pad, which demonstrates that PPAR is
more abundant in stromal cells than in epithelial cells.
To investigate the role of PPAR in mammopoiesis, we mon-
itored ductal and alveolar development as well as mammary
function in fl/fl; MC and fl/fl; WC mice. Ductal elongation and
branching during puberty were normal upon inactivation with
both the fl/fl; MC(D) and (F) line (Fig. 2B). Similarly, the
formation and differentiation of the alveolar compartment ap-
peared normal in fl/fl; WC and fl/fl; MC(D) mice (Fig. 3), and
the dams could support their litters. However, pregnancy-me-
diated alveolar development in fl/fl; MC(F) mice was impaired,
and the fat pad was rarely filled with lobules (Fig. 3). Those
dams that had only a sparsely developed lobular compartment
could not nurse their pups.
To investigate whether the mammary gland phenotype in
fl/fl; MC(F) mice was autonomous to the epithelium or caused
by systemic defects, we performed mammary epithelial trans-
plants. Epithelium from fl/fl; MC(F) mice was transplanted into
the cleared fat pad of athymic nude mice, and mammary de-
velopment was evaluated at parturition. At parturition, fl/fl;
MC(F) mammary epithelium had developed normally, and the
fat pad was filled with secretory alveoli (Fig. 3). These results
demonstrate that the incomplete mammary development in
fl/fl; MC(F) mice was not the result of a primary defect in the
epithelium, but rather a secondary defect.
PPAR Ablation from the Epithelial Compartment Did Not
Induce Mammary Tumors—PPAR is highly expressed in
FIG. 3. Histological analyses of mammary tissues from PPAR
fl/fl; Cre and PPAR fl/fl mice. Mammary tissues from PPAR fl/fl;
WC/MC(D)/MC(F) (panels I, III, and V) and PPARfl/fl control (panels
II, IV, and VI) mice were harvested at day 1 lactation. Panels VII and
VIII, mammary tissues were harvested from transplanted PPAR fl/fl;
MC(F) mammary epithelium into wild type mice at day 1 lactation.
Original magnification: 200.
FIG. 4. Reduced fertility in PPAR fl/fl; MC(F) mice. Left, aver-
age days of mating for PPAR fl/fl; MC(F) mice conception (p  0.01).
The data were from 24 fertile PPAR fl/fl; MC(F) mice and 32 control
mice. Right, the average number of pups from the first pregnancy (24
litters from PPAR fl/fl; MC(F) mice and 32 litters from PPAR fl/fl
control mice) and all pregnancies (46 litters from PPAR fl/fl; MC(F)
mice and 82 litters from PPAR fl/fl control mice). Data are expressed
as mean  S.D.
FIG. 2. The role of PPAR during mammary development. A,
expression pattern of the PPAR gene in mammary gland by Northern
blot analysis. B, whole mount analyses of mammary tissues from
PPAR fl/fl; Cre and PPAR fl/fl virgin mice. WAP-Cre and MMTV-
Cre(F) mammary tissues were from 8-week-old virgins; MMTV-Cre(D)
were from 20-week-old mice.



















breast cancer cell lines and infiltrating ductal breast adenocar-
cinomas (15), and the activation of PPAR has been known to
inhibit growth and induce apoptosis and terminal differentia-
tion of breast cancer cells in vitro and in vivo (15, 17). Based on
these observations, we hypothesized that the loss of PPAR
would sensitize mice to tumor formation. To investigate this
possibility, we observed more than 30 PPAR fl/fl; MC mice, 20
fl/fl; WC mice, and an equal number of control mice over a
period of 12 months. These mice were bred ad libidum. None of
these mice developed tumors over the 12 months. After 15
months 2 fl/fl; MC mouse and 1 control mouse developed breast
tumors. These results suggest PPAR is not a strong and dom-
inant tumor suppressor.
Loss of PPAR in the Ovary Results in Reduced Fertility—
PPAR has been found in bovine (27–29), rat (30, 31), and
human (32) ovaries. Reverse transcription-PCR results con-
firmed that the PPAR gene is also expressed in the mouse
ovary (data not shown). One-third (11/35) of fl/fl; MC(F) fe-
males were infertile, and the remainder exhibited impaired
fertility. On the average fl/fl; MC(F) conceived after 22 days of
mating, while it took control mice only 8 days (p  0.01) (Fig.
4). In addition, litter sizes of fl/fl; MC(F) dams were small (3 
2 pups), while there were 6  3 pups in the fl/fl mice (p  0.01)
(Fig. 4).
To investigate the cause of the impaired fertility, we per-
formed morphometric analyses on ovaries from 3-month-old
fl/fl; MC(F) (n  4) and fl/fl females (n  4). There was no
significant difference in the numbers of primordial (9720 
3595 versus 9460  5008 in fl/fl; MC(F) versus fl/fl ovaries, p 
0.935), primary (2940  1253 versus 2760  847, p  0.819)
and preantral/antral (5240  1201 versus 6620  2145, p 
0.304) follicles. We also treated fl/fl; MC(F) (n  2) and control
(n 2) mice with PMSG (5 IU/mouse) and hCG (5 IU/mouse) to
induce superovulation. There was no difference in the number
of oocytes (25 versus 20) released in response to PMSG.
Reduced fertility of PPAR fl/fl; MC(F) mice could also be the
result of decreased levels of progesterone. We therefore meas-
ured progesterone levels in virgin mice at the estrus day (n 
4 in each group). Although the progesterone level in fl/fl; MC(F)
mice (6.3  3.1 ng/ml) was lower than that in the control
(12.5  7.5 ng/ml) mice, the difference was not significant (p 
0.204). We also measured the progesterone levels in mice in-
FIG. 5. Normal B- and T-cell population in spleen of PPAR fl/fl; MMTV-Cre and control mice. Two-color FACS analysis of spleen from
6–8-week-old mice. Upper panels show staining with anti-B220 and anti-MacI antibodies (B-cell and monocyte surface marker, respectively) and
lower panels show anti-CD8/anti-CD4 staining (T-cell marker).



















jected with 5 IU of PMSG followed 48 h later by 5 IU of hCG
injection. Progesterone levels were 43.6  21.2 ng/ml in fl/fl;
MC(F) mice and 51.5  19.6 in fl/fl mice (n  6 in each group).
There was no significant difference. We collected and fixed the
ovaries from these virgin and pseudopregnant mice, and meas-
ured the size of the corpus luteum. There were no differences in
morphology or size of the corpus luteum between the fl/fl;
MC(F) and control mice ovaries.
We also examined the number of implantations in utero of
PPAR fl/fl; MC(F) and control mice. Implantation occurs be-
tween days 3.5 and 4 (33), and we counted implantation sites at
day 6.5 postcoitus. We found six implantation sites in one of the
three PPAR fl/fl; MC(F) mice but none in the other two. In the
two control mice we found five and seven implantation sites,
respectively. As described earlier (Fig. 1), Cre was not expressed
in the uterus, and the PPAR gene had remained intact.
B- and T-cells Develop in the Absence of PPAR—A possible
role for PPAR in the differentiation of B- and T-cells has been
reported (3, 34). To address whether the development of B- and
T-cells requires the presence of PPAR, we analyzed B- and
T-cell populations from spleen using FACS cytometry (Fig. 5).
In control mice, B-cells constitute 	50%, T-cells 35%, and
macrophages 5% of the total cells in spleen. The same ratio was
observed in spleens from PPAR fl/fl; MC(F) mice. These re-
sults suggest that PPAR is not required for the generation of
B- or T-cells.
DISCUSSION
A variety of functions have been attributed to PPAR. Acti-
vation of PPAR promotes differentiation and induces apo-
ptosis in a broad range of human malignant cell lines, including
breast cancer (15, 17), prostate cancer (18), non-small cell lung
cancer (35), and liposarcomas (36). Furthermore activation of
PPAR reduces tumor progression in xenograft models of pros-
tate (18) and colon (37) cancers, and it induces regression or
stasis of DMBA (9,10-climethyl-1,2-benzanthracene)-induced
tumors (14, 16). In contrast with this, other studies show that
activation of PPAR promotes the development of colon tumors
in C57BL/6-APC/mice (38, 39). The use of mice in which the
PPAR gene is inactivated should shed light on the role of
PPAR on normal development, physiology, and tumorigene-
sis. Because traditional PPAR-null mice are embryonic lethal
(20), we have now investigated the role of PPAR through the
deletion of the gene in several cell types using Cre-loxP-medi-
ated recombination. Inactivation of the PPAR gene in mam-
mary epithelium with WAP-Cre or MMTV-Cre (D) mice did not
interfere with normal development during pregnancy, and lac-
tation was not impaired. Thus unlike other members of the
steroid receptor family (40), PPAR is not essential for ductal
and lobulo-alveolar development. Furthermore, we did not ob-
serve an increased incidence of mammary tumors. This sug-
gests that PPAR by itself is not vital for development and is
not a dominant tumor suppressor. It is possible that other
members of this family, such as PPAR and PPAR, compen-
sate for the loss of PPAR, similar to the pRb family (41). The
expression of an active oncogene in mammary epithelium de-
void of PPAR (possibly through a transgene) will eventually
establish whether PPAR has any tumor suppressor function
in the breast.
Inactivation of the PPAR gene with an MMTV-Cre(F) trans-
gene resulted in impaired fertility and abrogated mammary
development. However, lack of functional mammary develop-
ment is probably a consequence to the ovarian dysfunction for
several reasons. Results of mammary epithelial transplants
demonstrated the PPAR-null epithelium could develop into a
differentiated mammary gland. In situ hybridization has
shown that PPAR mRNA is present in the ovary and primar-
ily in the granulosa cells of developing follicles, but not in the
oocytes (31). Following the luteinizing hormone surge, levels of
PPAR mRNA decline suggesting a role in ovarian function
(31). Furthermore, the MMTV-Cre(F) line of transgenic mice
expresses Cre in oocytes, granulosa cells, and the corpora lutea,
and the impaired fertility could be the result of subfunctional
physiology of these cell types.
PPAR fl/fl; MC(F) mice appeared to ovulate normally but
exhibited impaired implantation. Because Cre was not ex-
pressed in uterine tissue and the PPAR gene was intact,
uterine dysfunction can be ruled out. In the mouse, secretion of
progesterone from newly formed corpora lutea, accompanied by
preimplantation ovarian estrogen secretion on day 4 of preg-
nancy, is critical for the establishment of uterine receptivity for
implantation (42). The activation of PPAR has been shown to
affect progesterone production. PPAR ligands inhibited pro-
gesterone production in cultured human and porcine granulosa
cells (43); however, they stimulated the secretion of both pro-
gesterone and E2 in cultured rat granulosa cells (31). In our in
vivo study, progesterone levels were reduced in virgin mice
upon inactivation of the PPAR gene in granulosa cells and the
corpora lutea. These mice had normal follicle numbers and
normal estrous cycles. When stimulated by PMSG/hCG injec-
tion the progesterone levels increased to the normal range, and
the morphology and size of the corpora lutea were normal,
suggesting the ovary was functional upon exogenous hormone
challenging. Under physiological conditions, the ovarian func-
tion might not be sufficient to induce implantation, which could
explain the reduced fertility of PPAR fl/fl; MC(F) mice.
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